Article by Zhang Xinyue of Golden Touch Planning a retreat for team building can be very daunting as it is a big responsibility there are several crucial points to incorporate. If it is done correctly and respect is paid to all members of staff, it will be a successful and …
By Mark Lamport-Stokes INDIAN WELLS, California (Reuters) – While Maria Sharapova's fellow players were shocked by the Russian's announcement that she failed a drug test at the Australian Open, most of them felt the “huge mistake” could have been avoided. World number three Agnieszka Radwanska of Poland described it as “a very sad day for tennis” but expressed the views of many by saying it was down to every player, via their doctor, to check whether prescribed medications were legal. Five-times grand slam champion Sharapova tested positive for meldonium, which some researchers have linked to increased athletic performance and endurance, after failing by her own admission to realize that it had been outlawed since Jan. 1.
Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, “transformational” merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the proceeds from its $40.5 billion sale to Teva to increase the size of existing drug businesses, expand into new therapy areas, and pursue larger deals. “We can accelerate our timing on transformational M&A,” Saunders said during the conference call, describing the sale to Teva as “reloading” its balance sheet.